|[February 10, 2014]
ALERT: The Rosen Law Firm Announces Investigation of Securities Fraud Claims Against The Medicines Company --- MDCO
NEW YORK --(Business Wire)--
The Rosen Law Firm, P.A. announces that it is investigating potential
securities fraud claims against The Medicines Company (Nasdaq:MDCO)
resulting from allegations that the Company may have issued materially
misleading business information to the investing public.
On February 10, 2014, the U.S. Food and Drug Administration ("FDA")
issued a report concerning Medicines Co. drug candidate Cangrelor,
designed to prevent blood clots. The report indicated that Cangrelor was
not shown to be as good or superior to a rival drug and a new trial
should be conducted before the drug is considered for approval. The
report also states that the CHAMPION trials "were conucted unethically"
and Cangrelor should not be approved "on that fact alone." On this news,
shares of The Medicines Company fell $1.80 per share, or by
approximately 5%, to close at $32.42 on February 10, 2014.
The Rosen Law Firm is preparing a class action lawsuit as a result of
this adverse information. If you purchased Medicines Co. securities, you
may visit the website at http://rosenlegal.com
to join the action. You may also contact Phillip Kim, Esq. or Kevin
Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail
at firstname.lastname@example.org or email@example.com.
The Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and shareholder
Attorney Advertising. Prior results do not guarantee a similar outcome.
[ Back To Technology News's Homepage ]